L. Kulik

Hepatology · Gastroenterology · 2009–2023

A researcher in the Science corpus: 10 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom L. Kulik trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jordi Bruix1 , 2
  2. J. Llovet
  3. H. B. EL‐SERAG
  4. C. Lo
  5. R. Salem
  6. Amit G. Singal
  7. M. Sherman
  8. J. Heimbach

Papers from L. Kulik's perspective

Ordered by how strongly the researchers L. Kulik trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  3. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
  4. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
  5. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
  6. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)
  7. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
  8. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (Hepatology)
  9. A model to predict survival in patients with end‐stage liver disease (Hepatology)
  10. Primary liver cancer: worldwide incidence and trends. (Gastroenterology)

Their papers